Covid-19 roundup: Pfiz­er/BioN­Tech spell out PhI­II pri­or­i­ty; Le­gal ex­perts urge FDA to re­frain from vac­cine EUAs

Milder side ef­fects among the el­der­ly were crit­i­cal in Pfiz­er and BioN­Tech’s choice of vac­cine can­di­date to send in­to Phase III test­ing, the com­pa­nies re­vealed in a preprint.

The Ger­man biotech dis­tin­guished its Covid-19 pro­gram right from the be­gin­ning by eval­u­at­ing four dif­fer­ent mR­NA con­structs. BNT162b1 and BNT162b2, two nu­cle­o­side-mod­i­fied RNAs for­mu­lat­ed in lipid nanopar­ti­cles, showed the most promis­ing re­sults in an­i­mal stud­ies and re­ceived fast track sta­tus in the US.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.